Nautilus Biotechnology (NAUT) Common Equity (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Common Equity data on file, last reported at $144.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 25.73% year-over-year to $144.4 million; the trailing twelve-month figure through Mar 2026 stood at $144.4 million (down 25.73% YoY), and the FY2025 full-year result was $157.0 million, down 24.8% from the prior year.
• Common Equity declined to $144.4 million in Q1 2026, from $157.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $349.7 million in Q1 2022 to a low of $144.4 million in Q1 2026.
• A 5-year average of $248.6 million and a median of $249.5 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 1050.43% in 2022 and slipped 25.73% in 2026, its largest moves.
• Tracing NAUT's Common Equity over 5 years: stood at $314.9 million in 2022, then retreated by 15.74% to $265.4 million in 2023, then declined by 21.34% to $208.7 million in 2024, then declined by 24.8% to $157.0 million in 2025, then slipped by 8.0% to $144.4 million in 2026.
• Business Quant data shows NAUT's Common Equity at $144.4 million in Q1 2026, $157.0 million in Q4 2025, and $169.1 million in Q3 2025.